Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021.
“Bellerophon remains focused on advancing its INOpulse® inhaled nitric oxide therapy in multiple high-value areas of unmet need as expeditiously as possible,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Enrollment in our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension continues to advance. We also anticipate top-line results from our Phase 2 dose escalation study of INOpulse in sarcoidosis, or PH-Sarc, later this year. Our
Aridis Pharmaceuticals Announces First Quarter 2021 Results
News provided by
Share this article
Share this article
LOS GATOS, Calif., May 11, 2021 /PRNewswire/ Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.
First Quarter Highlights
Announced the addition of a second inhaled monoclonal antibody ( mAb ) to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product s self-administered, at-home treatment modality, further differentiates the company s AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021.
[1] the HHS Office of Inspector General (OIG) said Visiting Nurse Association of Maryland (VNA) received overpayments of $2.1 million in 2015 and 2016. OIG audited a stratified random sample of 100 claims and found errors on 19 of them. As a result, VNA received overpayments of $25,295 for services provided in 2015 and 2016. “On the basis of our sample results, we estimated that VNA received overpayments of at least $2.1 million for the audit period,” according to OIG, which noted all the claims are outside the reopening period. OIG said VNA billed for services provided to beneficiaries who weren’t homebound or delivered services that were inconsistent with the plan of care, among other errors. VNA disagreed with most of OIG’s findings. In a letter to OIG, the home health agency said, “VNA stands firm that it was providing covered services,” and “the error rate does not support extrapolation.”
House Energy and Commerce to Hold Hearing on Drug Pricing Legislation
Senate
Senators Thune and Carper Reintroduce Bill on Chronic Disease Management
Administration
Biden Administration to Divert Raw Materials for COVID-19 Vaccine and Provide Other Supplies to India
CDC Issues New Guidance for Vaccinated Americans
FDA Panel Votes to Keep Tecentriq on the Market
FDA to Propose Menthol Ban in Next Year
HHS Will Distribute $1 Billion for Community Health Centers
HHS Removes Some Prescribing Barriers for Buprenorphine
Final Rules
CMS Extends Comprehensive Joint Replacement Model Demonstration for Three Years
Proposed Rules
CMS Issues Proposed Rule on Payment Rates and Policies for Inpatient and Long-Term Hospitals
Clinical Programming Director
Selah Freedom is a Faith-Based, Regional organization providing education and training throughout the country, as well as teen prevention, outreach, and safe housing in the Midwest and Southeast regions of the United States. Selah Freedom s headquarters is located in Sarasota, Florida. Selah Freedom exists to end sex trafficking and bring freedom to the exploited.
Selah Freedom s standards, policies, procedures, and programs are guided by Biblical Principles. Selah Freedom believes the Bible to be the inspired, infallible, authoritative Word of God. There is one God, eternally existent in three persons: Father, Son, and the Holy Spirit who is the ONLY way, truth, and life.